Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 6NIH 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11CNS 10Breast 8Gastrointestinal 5Sarcoma 4Other hematologic neoplasm 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Myeloid 1Lymphoid 1Endocrine 1

Conditions

Melanoma 2Uveal Melanoma 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × AZD 6244 × Dermatologic × Clear all
NCT01256359 2024-08-15

DOC-MEK

University of Oxford

Phase 2 Completed
83 enrolled 60 charts
Dermatologic

Melanoma

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

Columbia University

Phase 1 Completed
42 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡